The diffusion of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), enlightened the need to implement the pandemic preparedness with new antiviral agents able to block viral replication and endowed with broad-spectrum antiviral activity. Besides the classical proteases and polymerases, other viral encoded enzymes involved in key steps of the viral replication cycle are currently investigated as targets, to expand the drug portfolio and develop combinatory strategies to decrease the risk of selection drug-resistant variants. The human coronaviruses (hCoVs) helicase is a multidomain enzyme able to unwind DNA or RNA in an NTP-dependent manner with a 5’-3’ polarity. It couples two C-terminal RecA ATPase domains, characteristic of the 1B (SF1B) helicase superfamily, with three other domains: the N-terminal zinc-binding domain (ZBD), essential for the helicase activity, a stalk, and a 1B domain.is a key component of the viral genome replication complex and its sequence is highly conserved among hCoVs, making it a promising and attractive and still under-explored target for the development of new antiviral drugs with broad spectrum activity and potential applications for future emerging coronaviruses of human or animal interest.[1] In this study, with the goal of identifying potential Pan-hCoVs helicase inhibitors, we rationally designed and synthesized a library of compounds that were evaluated for their biological activity. A combination of biochemical assays and cell-based assays was used to test the enzymatic activities and the inhibition of viral replication of different hCoVs. The results revealed that all compounds inhibited both SARS-CoV-2 helicase-associated enzyme activities, namely NTPase and unwinding activity, showing IC50 values in the low micromolar range. Among them, several compounds also demonstrated potent antiviral effects, significantly inhibiting SARS-CoV-2 replication at low EC50 values in different cell lines, without causing notable cytotoxicity (CC50). Noteworthy, the compounds showed an additive effect when tested in combination with both Nirmatrevir and Remdesivir against the viral replication, supporting the hypothesis of drug combinations. Furthermore, some of the most promising candidates demonstrated antiviral activity against other human coronaviruses such as MERS-CoV and hCoV-229E, highlighting their potential as pan-hCoV inhibitors. These findings pave the way for further development of the identified compounds as antiviral agents targeting hCoV helicases for effective treatments against SARS-CoV-2 and other hCoVs, opening the door to the development of novel therapeutic agents that could address both current and future emerging coronavirus-related diseases.

Identification of Pan-hCoV inhibitors targeting viral helicases

Angela CORONA
Primo
;
ERica SANNA;Stefania MALOCCU;Roberta EMMOLO;Alessia ONALI;Rita MELEDDU;Sante SCOGNAMIGLIO;Elias MACCIONI;Simona DISTINTO;Enzo TRAMONTANO
2025-01-01

Abstract

The diffusion of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), enlightened the need to implement the pandemic preparedness with new antiviral agents able to block viral replication and endowed with broad-spectrum antiviral activity. Besides the classical proteases and polymerases, other viral encoded enzymes involved in key steps of the viral replication cycle are currently investigated as targets, to expand the drug portfolio and develop combinatory strategies to decrease the risk of selection drug-resistant variants. The human coronaviruses (hCoVs) helicase is a multidomain enzyme able to unwind DNA or RNA in an NTP-dependent manner with a 5’-3’ polarity. It couples two C-terminal RecA ATPase domains, characteristic of the 1B (SF1B) helicase superfamily, with three other domains: the N-terminal zinc-binding domain (ZBD), essential for the helicase activity, a stalk, and a 1B domain.is a key component of the viral genome replication complex and its sequence is highly conserved among hCoVs, making it a promising and attractive and still under-explored target for the development of new antiviral drugs with broad spectrum activity and potential applications for future emerging coronaviruses of human or animal interest.[1] In this study, with the goal of identifying potential Pan-hCoVs helicase inhibitors, we rationally designed and synthesized a library of compounds that were evaluated for their biological activity. A combination of biochemical assays and cell-based assays was used to test the enzymatic activities and the inhibition of viral replication of different hCoVs. The results revealed that all compounds inhibited both SARS-CoV-2 helicase-associated enzyme activities, namely NTPase and unwinding activity, showing IC50 values in the low micromolar range. Among them, several compounds also demonstrated potent antiviral effects, significantly inhibiting SARS-CoV-2 replication at low EC50 values in different cell lines, without causing notable cytotoxicity (CC50). Noteworthy, the compounds showed an additive effect when tested in combination with both Nirmatrevir and Remdesivir against the viral replication, supporting the hypothesis of drug combinations. Furthermore, some of the most promising candidates demonstrated antiviral activity against other human coronaviruses such as MERS-CoV and hCoV-229E, highlighting their potential as pan-hCoV inhibitors. These findings pave the way for further development of the identified compounds as antiviral agents targeting hCoV helicases for effective treatments against SARS-CoV-2 and other hCoVs, opening the door to the development of novel therapeutic agents that could address both current and future emerging coronavirus-related diseases.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I metadati presenti in IRIS UNICA sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono protetti da diritto d'autore, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11584/497469
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
  • OpenAlex ND
social impact